Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | CLL: the GREEN study

Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, explores the results of a subgroup analysis of the GREEN study (NCT01905943), evaluating obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).